The aim of this project is to implement the Tumor-First workflow at a Dutch national level.

The Tumor-First workflow involves testing of tumor tissue of all newly diagnosed epithelial ovarian cancer patients for the presence of pathogenic variants in ovarian cancer risk genes (e.g. BRCA). The tumor DNA test provides information on the effectiveness of treatment with PARP-inhibitors and it functions as a prescreen for germline testing. Reliability of the tumor DNA test was studied in validation studies and a regional implementation study was previously performed. National implementation will ensure equality in the genetic testing workflows for epithelial ovarian cancer patients in the Netherlands.  


This website has been developed to aid implementation of the Tumor-First workflow. It provides helpful material for clinicians involved in the diagnostic workflow. These materials have been developed in Dutch, however in case you are interested you are very welcome to contact us via the box below.


Contact box:

Tumor-First workflow        

Click on the article to read the full text.